5-Oxoproline prevents doxorubicin-induced cardiotoxicity and tumor growth
This study reveals a previously unrecognized dual role of 5-oxoproline, which functions both as an early biomarker for DOX-induced cardiotoxicity detection and as a therapeutic target that simultaneously inhibits cancer growth and protects the myocardium.
Authors
- Yihua Bei (ORCID: https://orcid.org/0000-0002-2727-7187)
- Z. Zhang (ORCID: https://orcid.org/0009-0008-7117-2121)
- Zhengyu Tao (ORCID: https://orcid.org/0000-0001-7040-042X)
- Shanshan Zeng (ORCID: https://orcid.org/0000-0001-5261-1805)
- Xinning Guo (ORCID: https://orcid.org/0009-0009-6402-6422)
- Chen Wu (ORCID: https://orcid.org/0000-0002-0672-2122)
- Zi Wang (ORCID: https://orcid.org/0000-0002-2890-3944)
- Yinan Wang (ORCID: https://orcid.org/0000-0002-7203-2277)
- Meng Jiang (ORCID: https://orcid.org/0000-0003-0509-8927)
- Kun Qian (ORCID: https://orcid.org/0000-0003-1666-1965)
- Xiaoning Wang (ORCID: https://orcid.org/0000-0002-6475-5635)
- Huijuan Dai
- Jun Pu
Institutions
- Shanghai Jiao Tong University (CN)
- Renji Hospital (CN)
Publication Details
- Journal
- Redox Biology
- Published
- 2025-07-05
- DOI
- https://doi.org/10.1016/j.redox.2025.103753
- Citations
- 7
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 9.72
Funders
- Shanghai Municipal Health Commission
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality